<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869605</url>
  </required_header>
  <id_info>
    <org_study_id>N-26-2021</org_study_id>
    <nct_id>NCT04869605</nct_id>
  </id_info>
  <brief_title>1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin Ratio as a Potential Biomarker for Islet β-cell Function and Insulin Resistance Among Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin Ratio as a Potential Biomarker for Islet β-cell Function and Insulin Resistance Among Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperglycemia is a major risk factor for the micro- and macro-vascular complications of&#xD;
      diabetes . Lowering blood glucose levels has been shown to reduce the incidence of diabetes&#xD;
      complications.&#xD;
&#xD;
      Therefore, there is a need for a simple surrogate biochemical marker for glycemic&#xD;
      variability. Glycated hemoglobin (HbA1c) is the standard clinical measurement used to monitor&#xD;
      glycemic status and is recommended to assess control of diabetes over the preceding 2-3&#xD;
      months. However, being a measure of mean glucose, it does not reflect glucose variability.&#xD;
&#xD;
      It is well known that insulin secretion defects of islet β cells and/or tissue insensitivity&#xD;
      to insulin are common pathophysiological mechanisms of diabetes mellitus (DM) .&#xD;
&#xD;
      The elevation in the blood glucose level usually represents the degree of glucose metabolism&#xD;
      disorder, which is generally assessed by glycated hemoglobin A1c ( HbA1c) and indirectly&#xD;
      reflects the extent of β-cell function damage .&#xD;
&#xD;
      In the recent years, 1,5-anhydroglucitol (1,5-AG) has received attention as a short-term&#xD;
      blood glucose index that reflects the average blood glucose level 1,5 AG reflects the average&#xD;
      maximum blood glucose level during the past 1-2 weeks and is reported to be a more sensitive&#xD;
      marker of glucose variability and postprandial hyperglycemia than HbA1c, even for patients&#xD;
      with prediabetes and for those with well or moderately controlled diabetes .&#xD;
&#xD;
      (1,5 AG ) is structurally similar to glucose . Due to this similarity, glucose inhibits renal&#xD;
      reabsorption of 1,5 AG by competitive inhibition ,resulting in an inverse correlation of 1,5&#xD;
      AG with hyperglycemia .&#xD;
&#xD;
      1,5-AG levels are acting as an effective supplement to HbA1c. Additionally, previous study&#xD;
      showed that 1,5-AG and HbA1c had opposite curves with increasing blood glucose levels;&#xD;
      specifically, with the increase in HbA1c levels, 1,5-AG levels decreased significantly .&#xD;
      Therefore, we speculate a ratio of 1,5- AG / HB A1C in relation to islet β-cell function and&#xD;
      insulin resistance.&#xD;
&#xD;
      The aim of our study was to evaluate the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol&#xD;
      / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among&#xD;
      patients with type 2 diabetes .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes</measure>
    <time_frame>6 months</time_frame>
    <description>1,5 anhydroglucitol serum level, V level and 1,5 anhydroglucitol / HbA1c ratio</description>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio</intervention_name>
    <description>the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A case control study including 90 subjects aged 20 to 70 years, 45 healthy subjects as a&#xD;
        control group and 45 patients with type 2 DM .Patients will be collected from the&#xD;
        endocrinology outpatient clinic, Kasr El Ainy, Cairo University. Patients will be divided&#xD;
        into 2 groups, (group I) 45 patients with type 2 DM and (group II) 45 non DM as control&#xD;
        group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 20 to 70 years old with controlled and uncontrolled type 2 DM.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  : type 1 DM,&#xD;
&#xD;
          -  thyroid dysfunction,&#xD;
&#xD;
          -  chronic kidney disease,&#xD;
&#xD;
          -  chronic liver disease,&#xD;
&#xD;
          -  cancer patients,&#xD;
&#xD;
          -  cystic fibrosis,&#xD;
&#xD;
          -  acute and chronic infection and&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nehal H Elsaid</last_name>
    <phone>01004389020</phone>
    <phone_ext>02</phone_ext>
    <email>nihalhamdyelsaid@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <state>Manial</state>
        <zip>11521</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Youssry, M.D.</last_name>
      <phone>01004389020</phone>
      <phone_ext>01004389020</phone_ext>
      <email>mona55508@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>-Janssen J, van den Berg E, Zinman B , Espeland MA , Geijselaers S LC et al., (2019) . HbA(1c), insulin resistance, and β-cell function in relation to cognitive function in type 2 diabetes: the CAROLINA Cognition Substudy. Diabetes Care 42(1):e1-e3. -Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, Defronzo RA et al ., (2011) . The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care. 2011 Apr;34(4):1006-10. -Kim MJ, Jung HS, Hwang-Bo Y, Cho SW, Jang HC, Kim SY et al ., (2013) . Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol. 2013;50:505-10.</citation>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mona Youssry Helmy</investigator_full_name>
    <investigator_title>Lecturer of internal medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not to share</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

